Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High – Here’s What Happened

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) hit a new 52-week high on Thursday . The company traded as high as $18.12 and last traded at $16.96, with a volume of 2164145 shares trading hands. The stock had previously closed at $17.15.

Wall Street Analysts Forecast Growth

DFTX has been the topic of a number of recent research reports. Jones Trading assumed coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective on the stock. Royal Bank Of Canada lowered their target price on Definium Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, November 7th. Lifesci Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and an average price target of $30.33.

Definium Therapeutics Stock Performance

The stock has a market cap of $1.67 billion, a PE ratio of -8.32 and a beta of 2.57. The stock has a fifty day moving average of $12.93 and a 200-day moving average of $11.31. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.26). On average, equities analysts forecast that Definium Therapeutics, Inc. will post -1.35 EPS for the current year.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the sale, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,667 shares of company stock valued at $561,071 over the last three months. 2.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BIT Capital GmbH acquired a new stake in Definium Therapeutics during the 3rd quarter valued at approximately $26,000. Fifth Third Bancorp boosted its stake in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after buying an additional 3,300 shares during the last quarter. Sound Income Strategies LLC purchased a new position in shares of Definium Therapeutics during the 3rd quarter valued at approximately $46,000. Russell Investments Group Ltd. grew its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after buying an additional 1,796 shares during the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.